FDA Fast-Tracks Cancer Drug for Autism Treatment in Children

Parents of children with autism now have a new treatment option after the FDA fast-tracked approval of leucovorin in September 2025. The generic drug, traditionally used to support cancer patients during chemotherapy, works as a folic acid supplement for children with folic acid deficits linked to autism symptoms.

Seven-year-old Christopher Wilson of Las Vegas is one of the first Nevada children trying the medication. His father Shawn turned to leucovorin after years of searching for ways to help his nonverbal son, who was diagnosed with autism as an infant after doctors initially thought he was blind.

The autism community has embraced the treatment with cautious optimism. Some parents online have reported children beginning to speak within days of starting the medication, leading families like the Wilsons to call it their "little bottle of hope."

After 30 days on leucovorin, Christopher hasn't shown major improvements yet. Dr. Devraj Chavda, one of the few pediatric neurologists in Las Vegas prescribing the medication, emphasizes that families need realistic expectations about what treatment can achieve.

"We shouldn't look at autism as something that is curable," Dr. Chavda tells families. Even if children begin speaking on the medication, doctors still need to identify what was blocking their speech development in the first place.

The treatment faces some practical challenges. Because leucovorin is generic, doctors worry about quality consistency across different manufacturers, which could affect how well the medication works for autism symptoms.

Finding specialists who can prescribe and monitor the treatment remains difficult in Nevada. The state's shortage of pediatric neurologists means families often wait months just to get appointments, adding another hurdle to an already challenging journey.

The federal government plans to launch a major study of leucovorin for autism in 2026. Until then, children like Christopher receive the medication through their doctors, who carefully track results to understand how it works outside formal trials.

Why This Inspires

Despite not seeing immediate results, Shawn Wilson continues giving his son the medication every day. His commitment reflects what countless autism parents face: the willingness to try every safe option that might help their child thrive.

The approval also represents something bigger than one medication. It shows the medical community is actively searching for new ways to support children with autism and their families, even repurposing existing drugs to find answers faster.

For families navigating autism diagnoses, just having a new option brings relief after years of limited choices. Whether leucovorin becomes a breakthrough or a stepping stone to better treatments, it represents forward momentum in understanding and supporting neurodivergent children.

Shawn Wilson sums up what drives him: "You just want to do the best thing you can do for your kid."